N,N′-substituted-1,3-diamino-2-hydroxypropane...

Details N,N′-substituted-1,3-diamino-2-hydroxypropane... N,N′-substituted-1,3-diamino-2-hydroxypropane...

2006-12-11

2010-06-01

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S268100

Reexamination Certificate

active

07727997

ABSTRACT:
Disclosed are compounds of the formulawherein the variables RN, RC, R1, R25, R2, and R3are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of disorders such as Alzheimer's Disease.

REFERENCES:
patent: 4351842 (1982-09-01), Coles
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5559256 (1996-09-01), Gordon et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5720936 (1998-02-01), Wadsworth et al.
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5744346 (1998-04-01), Chrysler et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5850003 (1998-12-01), McConlogue et al.
patent: 5877015 (1999-03-01), Hardy et al.
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 5912410 (1999-06-01), Cordell
patent: 5942400 (1999-08-01), Anderson et al.
patent: 6045829 (2000-04-01), Liversidge et al.
patent: 0 652 009 (1995-05-01), None
patent: 98/22597 (1998-05-01), None
patent: 98/33795 (1998-08-01), None
patent: 00/03819 (2000-01-01), None
patent: 00/17369 (2000-03-01), None
patent: 00/47618 (2000-08-01), None
patent: 01/23533 (2001-02-01), None
patent: 01/64001 (2001-04-01), None
patent: 01/10387 (2001-08-01), None
patent: 02/02505 (2002-01-01), None
patent: 02/02512 (2002-01-01), None
patent: 02/02518 (2002-01-01), None
patent: 02/02520 (2002-01-01), None
patent: 02/14264 (2002-02-01), None
B. Gisin, “Aminodiacylhydrazin-Umlagerung,” Helv. Chim. Acta, vol. 53, 1030-1043 (1970).
Bennett, Frank, “The Synthesis of Novel HIV-Protease Inhibitors via Silica Gel Assisted Addition of Amines to Epoxides,” Synlett, 703-704 (1993).
Burness et al., “β-Keto Acetals. I. Synthesis of Pyrazoles and Pyrimidines and the Steric Inhibition of Resonance in 5-Alkyl-1-p-nitrophenylpyrazoles,” J. Org. Chem., 21, 97-101 (1956).
Calderwood et al., “Organocerium reactions of benzamides and thiobenzamides: A direct synthesis of tertiary carbinamines,” Tet. Lett., 38:1241-1244 (1997).
Hyafil et al., “In Vitro and in Vivo Reversal of Multidrug Resistance by GF120918, an Acridonecarboxamide Derivative,” Cancer Research, 53, 4595-4602 (1993).
Dantzig et al., “Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Potent Cyclopropyldibenzosuberane Modulator,” Cancer Research, 56:4171-4179 (1996).
Miyaura et al., “Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds,” Chem. Rev., 95:2457-2483 (1995).
Ciganek, Engelbert, “Tertiary Carbinamines by Addition of Organocerium Reagents to Nitrites,” J. Org. Chem., 57:4521-4527 (1992).
Citron et al., “Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production,” Nature, 360:672-674 (1992).
Witherspoon et al., “Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918,” Clin. Cancer Res., 2:7-12 (1996).
Daves et al., “Pyrimidines. XIII. 2- and 6-Substituted 4-Pyrimidinecarboxylic Acids (1a),” Midwest Research Institute, J. Heterocycl. Chem., 1:130-133 (Jul. 1964).
Emilien, Prospects for Pharmacological Intervention in Alzheimer Disease, Arch. Neurol. 57:454-459 (2000) [name spelled incorrectly in parent IDS].
Organic Syntheses, Collective vol. 2, Edited by A.H. Blatt, John Wiley & Sons, 313-315 (1961).
Felman et al., “Synthesis and antiulcer activity of novel 5-(2-ethenyl substituted)-3(2H)-furanones,” J. Med. Chem., 35:1183-1190 (1992).
Bold et al., “New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical Development,” J. Medicinal Chemistry, 41:3387-3401 (1998).
Games et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F -amyloid precursor protein,” Nature, 373:523-527 (1995) [name spelled incorrectly in parent IDS].
Hardy et al., “Framing β-amyloid,” Nature Genet., 1:233-234 (1992).
Plouvier et al., “Synthesis of Two New Thiazole-containing Oligopeptides as Potential DNA Minor Groove Binding Analogs of Netropsin,” Heterocycles, 32(4):693-701 (1991).
Hussain et al., “Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase,” Mol. Cell. Neurosci., 14:419-427 (1999).
Gould, Philip, “Salt selection for basic drugs,” International Journal of Pharmaceutics, 33:201-217 (1986).
Deno et al., “Protonated cyclopropane intermediates in the reactions of cyclopropanecarboxylic acids,” J. Am. Chem. Soc., 92:3700-3703 (1970).
Tang et al., “Models for metal binding sites in zinc enzymes. Syntheses of tris[4(5)-imidazolyl]carbinol (4-TIC), tris(2-imidazolyl)carbinol (2-TIC), and related ligands, and studies on metal complex binding constants and spectra,” J. Am. Chem. Soc., 100:3918-3922 (1978).
Diercks et al., “Tris(benzocyclobutadieno)benzene, the triangular [4]phenylene with a completely bond-fixed cyclohexatriene ring: cobalt-catalyzed synthesis from hexaethynylbenzene and thermal ring opening to 1,2:5,6:9,10-tribenzo-3,4,7,8,11,12-hexadehydro[12]annulene,” J. Am. Chem. Soc., 3150-3152 (1986).
Snyder et al., “Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids,” J. Am. Chem. Soc., 60:105-111 (1938).
Schapira et al., “3-Oxo-1,2-benzoisothiazoline-2-acetic Acid 1,1-Dioxide Derivatives. I. Reaction of Esters with Alkoxides,” J. Heterocyclic Chem., 17:1281-1288 (1980).
Grunewald et al., “Examination of the Role of the Acidic Hydrogen in Imparting Selectivity of 7-(Aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) Toward Inhibition of Phenylethanolamine N-Methyltransferase vs the 2-Adrenoceptor,” J. Med. Chem., 40:3997-4005 (1997).
Martin et al., “Cyclopropane-Derived Peptidomimetics. Design, Synthesis, Evaluation, and Structure of Novel HIV-1 Protease Inhibitors,” J. Med. Chem., 41:1581-1597 (1998).
Alterman et al., “Design and Synthesis of New Potent C2-Symmetric HIV-1 Protease Inhibitors. Use of L-Mannaric Acid as a Peptidomimetic Scaffold,” J. Med. Chem., 41:3782-3792 (1998).
Cushman et al., “Synthesis of Analogs of 2-Methoxyestradiol with Enhanced Inhibitory Effects on Tubulin Polymerization and Cancer Cell Growth,” J. Med. Chem., 40:2323-2334 (1997).
Amblard et al., “Synthesis and Characterization of Bradykinin B2 Receptor Agonists Containing Constrained Dipeptide Mimics,” J. Med. Chem., 42:4193-4201 (1999).
Getman et al., “Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere,” J. Med. Chem., 36:288-291 (1992).
Vazquez et al., “Inhibitors of HIV-1 Protease Containing the Novel and Potent (R)-(Hydroxyethyl)sulfonamide Isostere,” J. Med. Chem., 38:581-584 (1994).
Minutolo et al., “Salicylaldoxime Moiety as a Phenolic “A-Ring” Substitute in Estrogen Receptor Ligands,” J. Med. Chem., 4288-4291 (2000).
Martin et al., “Cyclopropane-Derived Peptidomimetics. Design, Synthesis, and Evaluation of Novel Enkephalin Analogues,” J. Org. Chem., 65:1305-1318 (2000).
Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci., 66(1):1-19 (1977).
Kang et al., “The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor,” Nature, 325:733-736 (1987).
Kitaguchi et al., “Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity,” Nature, 331:530-532 (1988) [year is incorrect in parent IDS].
Klumpp et al., “Lithiation of cyclopropylcarbinols,” J. Am. Chem. Soc.,

Affiliated with

Also associated with

Rating

N,N′-substituted-1,3-diamino-2-hydroxypropane... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N,N′-substituted-1,3-diamino-2-hydroxypropane..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N,N′-substituted-1,3-diamino-2-hydroxypropane... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4229266